GH Research (GHRS) Cash from Operations (2020 - 2026)
GH Research (GHRS) posted quarterly Cash from Operations of 12330000.0 for Q4 2025, down 18.04% year-over-year from 15043118.43 in Q4 2024, and up 9.88% quarter-over-quarter from 13682000.0 in Q3 2025.
Analysis
GH Research (GHRS) Cash from Operations (2020 - 2026) Analysis & Trends
GH Research's Cash from Operations history runs 6 years deep, the most recent figure standing at 12330000.0 for Q4 2025.
- In Q4 2025, Cash from Operations fell 18.04% year-over-year to 12330000.0; the TTM figure through Dec 2025 stood at 43552000.0 (down 3.0% YoY), while the FY2025 annual figure was 43552000.0, down 3.0% from the prior year.
- Cash from Operations for Q4 2025 stood at 12330000.0, up from 13682000.0 in the prior quarter.
- The five-year high for Cash from Operations was 1087000.0 in Q1 2021, with the low at 13682000.0 in Q3 2025.
- The 5-year median for Cash from Operations is 8770000.0 (2025), against an average of 8238400.0.
- The sharpest annual moves came in 2021 and 2022: Cash from Operations sank 11864.94% in 2021, then advanced 12.68% in 2022.
- GH Research's Cash from Operations stood at 3758000.0 in 2021, then sank by 95.45% to 7345000.0 in 2022, then plunged by 59.56% to 11720000.0 in 2023, then rose by 10.87% to 10446000.0 in 2024, then fell by 18.04% to 12330000.0 in 2025.
- Business Quant data shows GHRS's Cash from Operations at 12330000.0 in Q4 2025, 13682000.0 in Q3 2025, and 8967000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | GH Research | 1.72 Bn | 1.36 Bn | - | -15.02 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.02 Mn |
| Mar 31, 2026 | -10.67 Mn |
| Dec 31, 2025 | -12.33 Mn |
| Sep 30, 2025 | -13.68 Mn |
| Jun 30, 2025 | -8.97 Mn |
| Mar 31, 2025 | -8.57 Mn |
| Dec 31, 2024 | -10.45 Mn |
| Sep 30, 2024 | -12.31 Mn |
| Jun 30, 2024 | -9.94 Mn |
| Mar 31, 2024 | -9.60 Mn |
| Dec 31, 2023 | -8.09 Mn |
| Sep 30, 2023 | -10.34 Mn |
| Jun 30, 2023 | -8.03 Mn |
| Mar 31, 2023 | -6.89 Mn |
| Dec 31, 2022 | -6.87 Mn |
| Sep 30, 2022 | -8.05 Mn |
| Jun 30, 2022 | -5.29 Mn |
| Mar 31, 2022 | -6.00 Mn |
| Dec 31, 2021 | -3.76 Mn |
| Sep 30, 2021 | -9.21 Mn |